etuvetidigene autotemcel

Trade name: Waskyra

Cell therapyapprovedOrphan Drug FDA

Approved

Dec 9, 2025

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jan 21, 2019 (NCT03837483)

Timeline

2010s

  1. Apr 30, 2010

    Orphan Drug Designation

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Dec 9, 2025

    Earliest FDA Approval

Indications

Mechanism of action

  • Stem CellSupplementation

    Stem Cell supplementation

Approval history

  • approvedDec 9, 2025

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03837483Phase 2Jan 21, 2019Orchard Therapeutics Limited, The Foundation Institute San Raffaele G. Giglio of Cefalù
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Orchard Therapeutics LimitedFor profit1112019
The Foundation Institute San Raffaele G. Giglio of CefalùAcademic/Hospital1012019
2 organizations
Page 1 / 1